Document is current
Any future updates will be listed below
-
Authors
Zhao, Haoxin
Park, Jaeoh https://orcid.org/0000-0003-2699-371X
Wang, Yuzhu
Chou, Yi-Ju
Li, Lemin
Raines, Lydia N.
Hsu, Michael https://orcid.org/0000-0003-3852-1461
Lin, Ching-Cheng
Cao, Wei
Ouyang, Yuli
Chen, Heng-Yi https://orcid.org/0000-0001-9283-6144
Zheng, Linghua
Li, Zihai https://orcid.org/0000-0003-4603-927X
Huang, Alex Y. https://orcid.org/0000-0002-5701-4521
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
Lio, Chan-Wang Jerry
Huang, Stanley Ching-Cheng https://orcid.org/0000-0002-6557-3737
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-22-135-01-IBCD)
Cancer Research Institute
Melanoma Research Foundation
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 1 October 2025
First Online: 29 October 2025
Competing interests
: P.-C.H. is a member of scientific advisory for Elixiron Immunotherapeutics and a cofounder of Pilatus Biosciences. The other authors declare no competing interests.
